Publications

Publications of Torsten Haferlach Leukemia Diagnostics Foundation

We see it as our central task to make our knowledge and our data and results available for discussion and to the community through lectures, further education and publications.

2022
2022 2021 2020 2019
2022

Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes

Woerner J, Huang Y, Hutter S, Gurnari C, Sánchez JMH, Wang J, Huang Y, Schnabel D, Aaby M, Xu W, Thorat V, Jiang D, Jha BK, Koyuturk M, Maciejewski JP, Haferlach T, LaFramboise T. Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes. Nat Commun. 2022;13(1):1038

Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia

Kubota Y, Zawit M, Durrani J, Shen W, Bahaj W, Kewan T, Ponvilawan B, Mori M, Meggendorfer M, Gurnari C, LaFramboise T, Feurstein S, Sekeres MA, Visconte V, Godley LA, Haferlach T, Maciejewski JP. Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia. Leukemia. 2022;36(12):2827-2834

Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms

Kongkiatkamon S, Terkawi L, Guan Y, Adema V, Hasipek M, Dombrovski T, Co M, Walter W, Awada H, Parker Y, Hutter S, Pagliuca S, Gurnari C, Rogers HJ, Meggendorfer M, Lindner DJ, Haferlach T, Visconte V, LaFramboise T, Jha BK, Maciejewski JP. Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms. Leukemia. 2022;36(8):2086-2096.

Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia

Kongkiatkamon S, Pagliuca S, Adema V, Nagata Y, Kerr CM, Walter W, Awada H, Hutter S, Gurnari C, Rogers HJ, Meggendorfer M, Saunthararajah Y, Haferlach T, Visconte V, Maciejewski JP. Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. Leukemia. 2022;36(4):1185-1188.

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

Kimura S, Montefiori L, Iacobucci I, Zhao Y, Gao Q, Paietta EM, Haferlach C, Laird AD, Mead PE, Gu Z, Stock W, Litzow M, Rowe JM, Luger SM, Hunger SP, Ryland GL, Schmidt B, Ekert PG, Oshlack A, Grimmond SM, Rehn J, Breen J, Yeung D, White DL, Aldoss I, Jabbour EJ, Pui CH, Meggendorfer M, Walter W, Kern W, Haferlach T, Brady S, Zhang J, Roberts KG, Blombery P, Mullighan CG. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood. 2022;139(24):3519-3531.

A study of TERT rare variants in myeloid neoplasia

Gurnari C, Wahida A, Pagliuca S, Durmaz A, Zawit M, Haferlach T, Maciejewski JP, Visconte V. A study of TERT rare variants in myeloid neoplasia. Hematol Oncol. 2022;40(4):812-817.

TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes

Gurnari C, Pagliuca S, Guan Y, Adema V, Hershberger CE, Ni Y, Awada H, Kongkiatkamon S, Zawit M, Coutinho D, Zalcberg IR, Ahn JS, Kim HJ, Kim DDH, Minden MD, Jansen JH, Meggendorfer M, Haferlach C, Jha BK, Haferlach T, Maciejewski JP, Visconte V. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood Adv. 2022; ;6(1):100-107.

Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia

Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, Branford S, Brown AL, Cargo CA, Döhner H, Falini B, Garcia-Manero G, Haferlach T, Hellström-Lindberg E, Kim AS, Klco JM, Komrokji RS, Loh ML, Loghavi S, Mullighan CG, Ogawa S, Tefferi A, Papaemmanuil E, Reiter A, Ross DM, Savona MR, Shimamura A, Skoda RC, Sole F, Stone RM, Orazi A, Walter MJ, Wu D, Ebert BL, Cazzola M. Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia. Blood 2022;140(21):2228-2247.

Donations

You wish to support the foundation’s work? Our donation account is:

HypoVereinsbank

IBAN: DE9374 3200 7300 2778 2329
BIC/SWIFT: HYVEDEMM433

Purpose of payment line 1:
THLDS

Purpose of payment line 2:
Address of donor

Contact

We will gladly answer your questions or provide you with information on the Foundation.

Telephone +49 (0)89 99015-0       Send an e-mail